Overview Long-term Extension of GTX-102 in Angelman Syndrome Status: ENROLLING_BY_INVITATION Trial end date: 2029-02-01 Target enrollment: Participant gender: Summary The primary objective of the study is to evaluate the long-term safety profile of GTX-102 in participants with Angelman Syndrome (AS)Phase: PHASE3 Details Lead Sponsor: Ultragenyx Pharmaceutical Inc